Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$75.00 USD

75.00
5,150,663

+0.02 (0.03%)

Updated May 30, 2024 04:00 PM ET

After-Market: $75.34 +0.34 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable

Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.

Boston Scientific (BSX) Faces Rising Costs, Competition

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

AHCO or BSX: Which Is the Better Value Stock Right Now?

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) and Scivita Medical Expand Partnership

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Abbott (ABT) Expands in Canada With First Eterna SCS Use

Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.

AHCO vs. BSX: Which Stock Is the Better Value Option?

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Envista (NVST) Down 5.8% Since Last Earnings Report: Can It Rebound?

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Boston Scientific (BSX) Grows IC Business With New FDA Nod

The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.

Why Is Boston Scientific (BSX) Up 2.1% Since Last Earnings Report?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shaun Pruitt headshot

C3.ai's (AI) Stock Is Soaring After Earnings But is it Time to Buy?

As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Boston Scientific (BSX) Completes First Case With Its PFA System

Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.

Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise

Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.

Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands

Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.

Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down

Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.

Here's Why You Should Invest in Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.

Envista (NVST) Q4 Earnings Miss Estimates, Margins Down

Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.

STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up

STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.